Role of Fenofibrate in Indirect Neonatal Hyperbilirubinemia: a Randomized Control Trial
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Fenofibrate accelerates bilirubin conjugation and excretion, decreasing the side effects of
prolonged unconjugated hyperbilirubinemia in neonates. It also reduces the duration of
phototherapy and thus the duration of stay in the hospital. This research is carried out to
improve standard protocol for the management of neonatal hyperbilirubinemia in the local
settings.